Base de dados : MEDLINE
Pesquisa : D09.698.629.305.423 [Categoria DeCS]
Referências encontradas : 1955 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 196 ir para página                         

  1 / 1955 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27772635
[Au] Autor:Pena-Polanco JE; Rondon-Berrios H
[Ad] Endereço:Renal-Electrolyte Division, University of Pittsburgh School of Medicine, Pittsburgh, PA.
[Ti] Título:Quiz Page November 2016: Kidney and Neurologic Complications in the Treatment of a Patient With Hepatic Encephalopathy.
[So] Source:Am J Kidney Dis;68(5):A15-A17, 2016 Nov.
[Is] ISSN:1523-6838
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Lesão Renal Aguda/etiologia
Delirium por Abstinência Alcoólica/complicações
Diarreia/induzido quimicamente
Fármacos Gastrointestinais/efeitos adversos
Encefalopatia Hepática/tratamento farmacológico
Hipernatremia/etiologia
Lactulose/efeitos adversos
Mielinólise Central da Ponte/etiologia
Quadriplegia/etiologia
[Mh] Termos MeSH secundário: Adulto
Encéfalo/diagnóstico por imagem
Diarreia/complicações
Hidratação
Encefalopatia Hepática/complicações
Seres Humanos
Hipernatremia/terapia
Imagem por Ressonância Magnética
Masculino
Mielinólise Central da Ponte/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Gastrointestinal Agents); 4618-18-2 (Lactulose)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171205
[Lr] Data última revisão:
171205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  2 / 1955 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28719336
[Au] Autor:Lee GO; McCormick BJJ; Seidman JC; Kosek MN; Haque R; Olortegui MP; Lima AAM; Bhutta ZA; Kang G; Samie A; Amour C; Mason CJ; Ahmed T; Yori PP; Oliveira DB; Alam D; Babji S; Bessong P; Mduma E; Shrestha SK; Ambikapathi R; Lang DR; Gottlieb M; Guerrant RL; Caulfield LE; For The Mal-Ed Network Investigators
[Ad] Endereço:Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.
[Ti] Título:Infant Nutritional Status, Feeding Practices, Enteropathogen Exposure, Socioeconomic Status, and Illness Are Associated with Gut Barrier Function As Assessed by the Lactulose Mannitol Test in the MAL-ED Birth Cohort.
[So] Source:Am J Trop Med Hyg;97(1):281-290, 2017 Jul.
[Is] ISSN:1476-1645
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The lactulose mannitol (LM) dual sugar permeability test is the most commonly used test of environmental enteropathy in developing countries. However, there is a large but conflicting literature on its association with enteric infection and host nutritional status. We conducted a longitudinal cohort using a single field protocol and comparable laboratory procedures to examine intestinal permeability in multiple, geographically diverse pediatric populations. Using a previously published systematic review to guide the selection of factors potentially associated with LM test results, we examined the relationships between these factors and mucosal breach, represented by percent lactulose excretion; absorptive area, represented by percent mannitol excretion; and gut barrier function, represented by the L/M ratio. A total of 6,602 LM tests were conducted in 1,980 children at 3, 6, 9, and 15 months old; percent lactulose excretion, percent mannitol excretion, and the L/M ratio were expressed as age- and sex-specific normalized values using the Brazil cohort as the reference population. Among the factors considered, recent severe diarrhea, lower socioeconomic status, and recent asymptomatic enteropathogen infections were associated with decreased percent mannitol excretion and higher L/M ratios. Poorer concurrent weight-for-age, infection, and recent breastfeeding were associated with increased percent lactulose excretion and increased L/M ratios. Our results support previously reported associations between the L/M ratio and factors related to child nutritional status and enteropathogen exposure. These results were remarkably consistent across sites and support the hypothesis that the frequency of these exposures in communities living in poverty leads to alterations in gut barrier function.
[Mh] Termos MeSH primário: Trato Gastrointestinal/fisiologia
Fenômenos Fisiológicos da Nutrição do Lactente
Lactulose/metabolismo
Manitol/metabolismo
Estado Nutricional
[Mh] Termos MeSH secundário: Envelhecimento
Feminino
Seres Humanos
Lactente
Alimentos Infantis
Masculino
Fatores Socioeconômicos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
3OWL53L36A (Mannitol); 4618-18-2 (Lactulose)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE
[do] DOI:10.4269/ajtmh.16-0830


  3 / 1955 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28560484
[Au] Autor:Pantham G; Post A; Venkat D; Einstadter D; Mullen KD
[Ad] Endereço:Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. gtrpantham@gmail.com.
[Ti] Título:A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis.
[So] Source:Dig Dis Sci;62(8):2166-2173, 2017 Aug.
[Is] ISSN:1573-2568
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND AIMS: Overt hepatic encephalopathy (HE) is a major cause of significant morbidity and mortality in patients with liver cirrhosis. We examined the frequency and profile of the precipitating factors resulting in hospitalizations for overt HE. METHODS: We conducted both retrospective and prospective studies to identify clinical precipitants of overt HE in patients with cirrhosis. The retrospective study patients were hospitalized at a large urban safety-net hospital, and the prospective study included the patients admitted at a liver transplant center. RESULTS: There were a total of 149 patients with cirrhosis and overt HE (91 males, mean age 55.3 ± 8.6 years) in the retrospective group and 45 patients (27 males, mean age 58.3 ± 8.2 years) in the prospective group of the study. The average MELD score was 16 ± 6.8 in the retrospective group and 22.7 ± 7.2 in the prospective group. Dehydration (46-76%), acute kidney injury (32-76%), lactulose nonadherence (about 50%), constipation (about 40%), and infections (20-42%) were the most frequently identified precipitants for hospitalization in retrospective and prospective groups. Multiple precipitants were identified in 60 (40.3%) patients in the retrospective group and 34 (76%) patients in the prospective group. CONCLUSIONS: Multiple concurrent precipitating factors were identified in the majority of patients with overt HE requiring hospitalization. Dehydration due to various causes was the most common precipitant of overt HE, followed by acute kidney injury (AKI), constipation, and infections. Prevention of dehydration, AKI, and constipation by close outpatient monitoring may be an effective measure to prevent hospitalization for overt HE in patients with cirrhosis.
[Mh] Termos MeSH primário: Encefalopatia Hepática/etiologia
Hospitalização/estatística & dados numéricos
Cirrose Hepática/complicações
[Mh] Termos MeSH secundário: Lesão Renal Aguda/complicações
Constipação Intestinal/complicações
Desidratação/complicações
Feminino
Fármacos Gastrointestinais/uso terapêutico
Seres Humanos
Lactulose/uso terapêutico
Cirrose Hepática/tratamento farmacológico
Masculino
Adesão à Medicação/estatística & dados numéricos
Meia-Idade
Estudos Prospectivos
Estudos Retrospectivos
Provedores de Redes de Segurança/estatística & dados numéricos
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Gastrointestinal Agents); 4618-18-2 (Lactulose)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170601
[St] Status:MEDLINE
[do] DOI:10.1007/s10620-017-4630-y


  4 / 1955 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28530560
[Au] Autor:Wang M; Gasmalla MAA; Admassu Tessema H; Hua X; Yang R
[Ad] Endereço:State Key Laboratory of Food Science and Technology, Jiangnan University, 214122 Wuxi, China; School of Food Science and Technology, Jiangnan University, 214122 Wuxi, China. Electronic address: wmm19900403@126.com.
[Ti] Título:Lactulose production from efficient isomerization of lactose catalyzed by recyclable sodium aluminate.
[So] Source:Food Chem;233:151-158, 2017 Oct 15.
[Is] ISSN:0308-8146
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:An efficient strategy for the synthesis of high-purity lactulose through chemical isomerization of lactose was developed using recyclable catalyst sodium aluminate. Maximum yield of 85.45±1.79% was obtained from 35% (w/v) of lactose using a 1:1M ratio of NaAlO -lactose after reaction at 60°C and pH 12 for 50min, with a purity ratio (Pu) of approximately 95%. Al(OH) precipitation from lactulose syrup through pH adjustment showing a superior decolorizing efficiency was implemented, which simplified the removal of catalyst and provided a convenient approach to achieve catalyst recovery. After dilution by 5 folds, nearly 98.5% of catalyst was removed through centrifugation and 85.50±1.81% of lactulose was recovered. Modified recycle use of catalyst without lactulose loss was carried out, after five consecutive recycles, total yield of lactulose (TY ) and new yield of lactulose (NY ) were of 80.44±1.05% and 73.87±0.50%, respectively, reflecting a high stability by using this recyclable methodology.
[Mh] Termos MeSH primário: Lactulose/química
[Mh] Termos MeSH secundário: Compostos de Alumínio
Catálise
Isomerismo
Lactose
Compostos de Sódio
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aluminum Compounds); 0 (Sodium Compounds); 0 (sodium aluminate); 4618-18-2 (Lactulose); J2B2A4N98G (Lactose)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170811
[Lr] Data última revisão:
170811
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170523
[St] Status:MEDLINE


  5 / 1955 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28429333
[Au] Autor:Ojetti V; Petruzziello C; Migneco A; Gnarra M; Gasbarrini A; Franceschi F
[Ad] Endereço:Department of Medical Sciences, Division of Gastroenterology, Catholic University of the Sacred Heart, Rome, Italy. veronica.ojetti@gmail.com.
[Ti] Título:Effect of Lactobacillus reuteri (DSM 17938) on methane production in patients affected by functional constipation: a retrospective study.
[So] Source:Eur Rev Med Pharmacol Sci;21(7):1702-1708, 2017 Apr.
[Is] ISSN:2284-0729
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Constipation is a common symptom affecting up to 30% of the Western population and is strongly associated with the presence of intestinal methanogens, which may directly inhibit motor activity. Two recent studies performed on adult and children affected by chronic constipation showed that the supplementation with L. reuteri significantly improved bowel movements. Whether its action is related to a decreasing of methane (CH4) production has never been tested. We have therefore designed a study aimed at testing this hypothesis. PATIENTS AND METHODS: Data of 20 adults (12 females, mean age 36.2 ± 13.7) affected by functional constipation, treated with the probiotic L. reuteri (DSM 17938) for 4 weeks who performed a H2/CH4 lactulose breath test (LBT) in our institution showing a CH4 production higher than 5 ppm were retrospectively analyzed from March to June 2015. Data recorded in their stool diary, reporting the frequency of defecations and stool consistency were also analysed, as well as the result of the LBT performed at the end of the treatment with L. reuteri. RESULTS: Four weeks of L. reuteri administration was associated with a significant decrease of mean CH4 production determined by LBT (from 20.8 ± 15 to 8.9 ± 8.6; p < 0.0001 CI 95%) and of AUC value (from 5101.5 ± 3571.13 to 2128.4 ± 2110.8; p < 0.0001 CI 95%). Moreover, a total disappearance of CH4 production (< 5 ppm at LBT) was observed in 11 patients, while, we did not observe any significant decrease of H2 production (from 13.2 ± 8.8 to 11.4 ± 7.3, CI 95%, n.s.). CONCLUSIONS: This study highlights for the first time the beneficial effect of Lactobacillus reuteri (DSM 17938) on chronic constipation, via a significant decrease of CH4 production.
[Mh] Termos MeSH primário: Constipação Intestinal/microbiologia
Lactobacillus reuteri
Metano/biossíntese
[Mh] Termos MeSH secundário: Adulto
Constipação Intestinal/metabolismo
Constipação Intestinal/terapia
Feminino
Seres Humanos
Lactulose
Probióticos/uso terapêutico
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
4618-18-2 (Lactulose); OP0UW79H66 (Methane)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170804
[Lr] Data última revisão:
170804
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170422
[St] Status:MEDLINE


  6 / 1955 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28410406
[Au] Autor:Kato T; Honda Y; Kurita Y; Iwasaki A; Sato T; Kessoku T; Uchiyama S; Ogawa Y; Ohkubo H; Higurashi T; Yamanaka T; Usuda H; Wada K; Nakajima A
[Ad] Endereço:Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan.
[Ti] Título:Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers.
[So] Source:PLoS One;12(4):e0175626, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND AIMS: The barrier function of the small intestinal mucosa prevents the introduction of undesired pathogens into the body. Breakdown of this barrier function increases intestinal permeability. This has been proposed to induce not only gastrointestinal diseases, including inflammatory bowel disease and irritable bowel syndrome, but also various other diseases, including allergies, diabetes mellitus, liver diseases, and collagen diseases, which are associated with this so called "leaky gut syndrome." As such, a method to prevent leaky gut syndrome would have substantial clinical value. However, no drugs have been demonstrated to improve disturbed intestinal permeability in humans to date. Therefore, we investigated whether a drug used to treat chronic constipation, lubiprostone, was effective for this purpose. METHODS: Healthy male volunteers were treated with lubiprostone (24 µg/day) for 28 days. Intestinal permeability was evaluated by measuring the lactulose-mannitol ratio (LMR) after administration of diclofenac and compared with an untreated group. The examination was conducted three times in total, i.e., at baseline before diclofenac administration and after 14 and 28 days of lubiprostone treatment. Blood endotoxin activity was also evaluated at the same time points. RESULTS: The final analysis was conducted on 28 subjects (14 in the lubiprostone group and 14 in the untreated group). The LMR after 28 days of treatment was significantly lower in the lubiprostone group than that in the untreated group (0.017 vs. 0.028, respectively; 95% confidence interval, -0.022--0.0001; p = 0.049). Blood endotoxin activity exhibited almost no change over time in the lubiprostone and untreated groups and displayed no significant differences at any time point of examination. CONCLUSIONS: This study is the first to report an improvement in leaky gut using an available drug in humans. The result suggests that lubiprostone may prevent and ameliorate "leaky gut syndrome". However, a pivotal trial is needed to confirm our finding.
[Mh] Termos MeSH primário: Agonistas dos Canais de Cloreto/uso terapêutico
Síndrome do Intestino Irritável/tratamento farmacológico
Lubiprostona/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Agonistas dos Canais de Cloreto/farmacologia
Cromatografia Líquida de Alta Pressão
Diclofenaco/farmacologia
Diclofenaco/uso terapêutico
Esquema de Medicação
Endotoxinas/sangue
Voluntários Saudáveis
Seres Humanos
Intestinos/efeitos dos fármacos
Intestinos/metabolismo
Lactulose/urina
Lubiprostona/farmacologia
Masculino
Manitol/urina
Espectrometria de Massas
Meia-Idade
Permeabilidade/efeitos dos fármacos
Projetos Piloto
Estudos Prospectivos
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Chloride Channel Agonists); 0 (Endotoxins); 144O8QL0L1 (Diclofenac); 3OWL53L36A (Mannitol); 4618-18-2 (Lactulose); 7662KG2R6K (Lubiprostone)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170504
[Lr] Data última revisão:
170504
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170415
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0175626


  7 / 1955 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28375406
[Au] Autor:Flamm SL
[Ad] Endereço:Liver Transplantation Program, Professor of Medicine, Northwestern Feinberg School of Medicine, Chicago, IL, USA.
[Ti] Título:Hot Topics in Primary Care: Diagnosis of Cirrhosis and Evaluation of Hepatic Encephalopathy: Common Errors and Their Significance for the PCP.
[So] Source:J Fam Pract;66(4 Suppl):S34-S39, 2017 Apr.
[Is] ISSN:1533-7294
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cirrhosis has become the focus of greater attention in recent years largely because of the increasing prevalence of 2 of its most common causes: chronic viral hepatitis and steatohepatitis (a subset of nonalcoholic fatty liver disease [NAFLD]). Cirrhosis is the result of progressive destruction and regeneration of the liver parenchyma due to chronic liver disease (CLD).
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Detecção Precoce de Câncer/métodos
Encefalopatia Hepática/diagnóstico
Encefalopatia Hepática/tratamento farmacológico
Cirrose Hepática/diagnóstico
Cirrose Hepática/tratamento farmacológico
Atenção Primária à Saúde/normas
[Mh] Termos MeSH secundário: Carcinoma Hepatocelular/diagnóstico
Carcinoma Hepatocelular/tratamento farmacológico
Carcinoma Hepatocelular/fisiopatologia
Educação Médica Continuada
Fármacos Gastrointestinais/uso terapêutico
Seres Humanos
Lactulose/uso terapêutico
Neoplasias Hepáticas/diagnóstico
Neoplasias Hepáticas/tratamento farmacológico
Neoplasias Hepáticas/fisiopatologia
Hepatopatia Gordurosa não Alcoólica/diagnóstico
Hepatopatia Gordurosa não Alcoólica/terapia
Guias de Prática Clínica como Assunto
Prevalência
Fatores de Risco
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Gastrointestinal Agents); 4618-18-2 (Lactulose)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170703
[Lr] Data última revisão:
170703
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170405
[St] Status:MEDLINE


  8 / 1955 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28346570
[Au] Autor:Chassagne P; Ducrotte P; Garnier P; Mathiex-Fortunet H
[Ad] Endereço:Pr Philippe Chassagne, Department of Geriatrics, Rouen University Hospital, 1 rue de Germont, 76 031 Rouen Cedex, France, Tel.: +33 2 32 88 90 42, E-mail: philippe.chassagne@univ-rouen.fr.
[Ti] Título:Tolerance and Long-Term Efficacy of Polyethylene Glycol 4000 (Forlax®) Compared to Lactulose in Elderly Patients with Chronic Constipation.
[So] Source:J Nutr Health Aging;21(4):429-439, 2017.
[Is] ISSN:1760-4788
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To assess the tolerance and potential nutritional consequences of long-term repeated doses of PEG 4000 (10 to 30 g/day) in elderly patients with chronic constipation as compared to lactulose (10-30 g/day). DESIGN: Single blind, randomised, multicentre, parallel group comparative study. SETTING: Community-dwelling patients and nursing homes residents aged 70 years and older with a history of chronic constipation. Treatment intervention: PEG 4000 (10-30 g/day) or lactulose (10-30 g/day) for six months. ASSESSMENTS: Clinical nutritional status (Mini Nutritional Assessment), blood and stool samples were taken at baseline and after three and six months for assay of nutritional and absorption parameters. A patient diary documented digestive symptoms and adverse events were recorded. Information on efficacy (stool frequency and consistency) was collected as a secondary outcome measure. RESULTS: Of the 316 patients screened, 245 eligible patients constituted the ITT population (PEG 4000: N = 118; lactulose group: N = 127). The proportion of patients receiving PEG 4000 with abnormal levels of electrolytes, nutritional markers or vitamins did not significantly change in the six months after initiating laxative treatment and do not differ between the two groups. After a D-xylose challenge test, the proportion of patients with abnormally low xylosaemia (suggesting malabsorption) varied from 24.6% at baseline to 35.8% after six months in the PEG 4000 group and from 29.1% to 42.4% in the lactulose group, with no significant between-group or within-group differences. The proportion of patients with poor nutritional status (MNA score <17) varied from 8.5% at baseline to 9.8% after 6 months in the PEG 4000 group and from 3.9% to 5.0% in the lactulose group. No changes in stool fat or total or soluble stool nitrogen were observed in the minority of patients for whom stool analysis was performed. A significantly higher stool frequency (p <0.05) and improved stool consistency (p <0.05) was observed in the PEG 4000 group compared to the lactulose group at each monthly evaluation period. CONCLUSIONS: After six months of treatment with PEG 4000, no clinically relevant changes in biochemical and nutritional parameters and no unanticipated treatment-related adverse events were detected, demonstrating the good clinical tolerance of PEG 4000 in this population of elderly constipated patients. This tolerance was associated with a better clinical efficacy of PEG 4000 compared to lactulose.
[Mh] Termos MeSH primário: Constipação Intestinal/tratamento farmacológico
Lactulose/uso terapêutico
Laxantes/uso terapêutico
Polietilenoglicóis/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Eletrólitos/análise
Fezes/química
Feminino
França
Seres Humanos
Lactulose/efeitos adversos
Laxantes/efeitos adversos
Masculino
Casas de Saúde
Estado Nutricional/fisiologia
Polietilenoglicóis/efeitos adversos
Método Simples-Cego
Resultado do Tratamento
Xilose/sangue
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE IV; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Electrolytes); 0 (Laxatives); 30IQX730WE (Polyethylene Glycols); 4618-18-2 (Lactulose); 4R4HFI6D95 (polyethylene glycol 4000); A1TA934AKO (Xylose)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE
[do] DOI:10.1007/s12603-016-0762-6


  9 / 1955 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28345979
[Au] Autor:Bardsley A
[Ad] Endereço:Senior Lecturer, Course Director Non-Medical Prescribing, Coventry University.
[Ti] Título:Assessment and treatment options for patients with constipation.
[So] Source:Br J Nurs;26(6):312-318, 2017 03 23.
[Is] ISSN:0966-0461
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Constipation is a common complaint for people of all ages, with prevalence increasing with age and during pregnancy. Women are more likely to be affected than men. Severity of constipation varies from person to person; most people experience short periods of constipation during their lives, including possibly after surgery, while others have constipation as a chronic long-term condition that can significantly affect their quality of life. There are a number of factors that can contribute to developing constipation including diets low in fibre, changes in lifestyle, side effects of certain medications and low fluid intake. People can successfully treat constipation by making changes to their diet and lifestyle. However, medication may be required to manage constipation for some.
[Mh] Termos MeSH primário: Constipação Intestinal/enfermagem
Dietoterapia
Laxantes/uso terapêutico
Avaliação em Enfermagem
[Mh] Termos MeSH secundário: Catárticos/uso terapêutico
Constipação Intestinal/diagnóstico
Constipação Intestinal/terapia
Gerenciamento Clínico
Seres Humanos
Lactulose/uso terapêutico
Metilcelulose/uso terapêutico
Peptídeos/uso terapêutico
Polietilenoglicóis/uso terapêutico
Qualidade de Vida
Extrato de Sena/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cathartics); 0 (Laxatives); 0 (Peptides); 30IQX730WE (Polyethylene Glycols); 4618-18-2 (Lactulose); 8013-11-4 (Senna Extract); 9004-67-5 (Methylcellulose); N0TXR0XR5X (linaclotide)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE
[do] DOI:10.12968/bjon.2017.26.6.312


  10 / 1955 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28333903
[Au] Autor:Blonska A; Konrad P; Chojnacki J; Chojnacki C
[Ad] Endereço:Department of Clinical Nutrition and Gastroenterology Diagnostics Medical University of Lódz, Poland.
[Ti] Título:[Evaluation of oro-cecal transit time in patients with irritable bowel syndrome with cereal products intolerance].
[Ti] Título:Ocena czasu pasazu ustno-katniczego u chorych z zespolem jelita nadwrazliwego i nietolerancjia produktów zbozowych..
[So] Source:Pol Merkur Lekarski;42(249):116-120, 2017 Mar 21.
[Is] ISSN:1426-9686
[Cp] País de publicação:Poland
[La] Idioma:pol
[Ab] Resumo:The main symptoms of irritable bowel syndrome (IBS) include abnormal frequency of bowel movements. On this basis, three main clinical types of the disease have been distinguished, i.e.: constipation (IBSC), diarrhea (IBS-D) and mixed-type (IBS-M) in accordance with the Rome III criteria. These disorders mainly affect the colon, but symptoms related to upper gastrointestinal tract are also often observed. AIM: The aim of the study was to assess the oro-caecal transit time in patients with irritable bowel syndrome with IgG-dependent hypersensitivity to cereal products. MATERIALS AND METHODS: The study was performed in three 30-person groups, aged 27-48 years (38.3 ± 10.4), in whom three types of IBS were diagnosed basing on the Rome III criteria . The control group consisted of 30 subjects without gastrointestinal symptoms. Orocaecal transit time was measured by hydrogen breath test using lactulose and Gastro + Gastrolyzer (Bedfont). RESULTS: The mean oro-caecal transit time was respectively in the groups: controls - 86,3 ± 5,95 min., IBS-C - 95,8 ±10,9 min. (p<0,05), IBS-D - 77,8 ± 8,21 min (p<0,01) and IBS-M - 80,6 ± 14,2 (p>0,05). There was a positive correlation between the transit time and disorder severity in IBS-C (p=0,05) group and negative in IBS-D (p<0,001) group. No significant correlation was found in IBS-M group (p=0,864). CONCLUSIONS: Disturbed digestic passage in the upper gastrointestinal tract may affect the clinical manifestation of irritable bowel syndrome.
[Mh] Termos MeSH primário: Grãos Comestíveis
Hipersensibilidade Alimentar/fisiopatologia
Trânsito Gastrointestinal
Imunoglobulina G
Síndrome do Intestino Irritável/fisiopatologia
[Mh] Termos MeSH secundário: Adulto
Testes Respiratórios
Feminino
Hipersensibilidade Alimentar/complicações
Hipersensibilidade Alimentar/imunologia
Seres Humanos
Síndrome do Intestino Irritável/diagnóstico
Síndrome do Intestino Irritável/etiologia
Lactulose
Masculino
Meia-Idade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulin G); 4618-18-2 (Lactulose)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170707
[Lr] Data última revisão:
170707
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170324
[St] Status:MEDLINE



página 1 de 196 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde